SynthesisBMJ open2022
Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006-2021: a systematic review and meta-analysis.
Synthesis in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Non-tuberculous mycobacterial infections among pulmonary tuberculosis suspected and confirmed patients in Ethiopia - A systematic review and meta analyses.BMC infectious diseases · 2025Pooled it
- Prevalence of nontuberculous mycobacteria in bronchiectasis: A systematic review and meta-analysis.New microbes and new infections · 2026Review
- Clinical features of nontuberculous mycobacteria and diagnosis with nanopore targeted sequencing: a retrospective cohort study.Annals of clinical microbiology and antimicrobials · 2026Article
- Clofazimine use for nontuberculous mycobacterial infections: 10-year experience in Belgium.BMC pulmonary medicine · 2026Observational
- Mycobacterial cell division arrest and smooth-to-rough envelope transition using CRISPRi-mediated genetic repression systems.FEBS open bio · 2026Article
- Lower airway dysbiosis in nontuberculous mycobacteria-positive bronchiectasis is associated with neutrophil extracellular trap-predominant severe phenotypes.American journal of respiratory and critical care medicine · 2026Article
- Brensocatib-Another Therapeutic "Window of Opportunity" for Patients with Bronchiectasis.Journal of clinical medicine · 2026Review
- Why a Mycobacterium Avium Infected Patient Showed a Positive Xpert MTB/RIF Result?Clinical case reports · 2026Article
- K-Means Cluster Identification of Nutritional Phenotypes in Patients with Nontuberculous Mycobacterial Pulmonary Disease and Correlation Analysis with Runyon Classification.Infection and drug resistance · 2026Article
- Clinical Characteristics and Risk Factors Analysis of Nontuberculous Mycobacterial Pulmonary Disease Complicated with Bronchiectasis.Infection and drug resistance · 2026Article
- Co-infection withFrontiers in medicine · 2026Review
- Analysis of nontuberculous mycobacterial infections in Saudi children from a tertiary care hospital perspective.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Characterization of Mycobacterium antarcticum sp. nov., a psychrotolerant member of the genus Mycobacterium isolated from Antarctic soil.Scientific reports · 2025Article
- Non-tuberculous mycobacterial infections among patients with suspected or confirmed pulmonary tuberculosis in Ethiopia: A systematic review and meta-analysis.IJID regions · 2025Review
- The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment.Infectious medicine · 2025Review
- Mycobacterium hainanense sp. nov. represents an emerging nontuberculous Mycobacterium associated with chronic pulmonary disease.Scientific reports · 2025Article
- Limited predictive power of known resistance genes for phenotypic drug resistance in clinicalAntimicrobial agents and chemotherapy · 2025Article
- Early surgical intervention for extensive nontuberculous mycobacterial pulmonary disease.IJTLD open · 2025Article
- Clinical significance of respiratory bacteria and mycobacteria isolates in adult bronchiectasis in Taiwan.ERJ open research · 2025Article
- Pulmonary Nontuberculous Mycobacteria Infection in Bronchiectasis: A Narrative Review of Current Status and Future.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo accurately estimate the global prevalence of non-tuberculous mycobacteria (NTM) in adults with non-cystic fibrosis (non-CF) bronchiectasis and to determine the proportion of NTM species and subspecies in clinical patients from 2006 to 2021.
designSystematic review and meta-analysis using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. DATA SOURCES: Medline, Embase, Cochrane Library and Web of Science were searched for articles published between 2006 and 2021. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included all the prospective or retrospective studies without language restrictions and all patients were adults (≥18 years of age) with non-CF bronchiectasis. The studies estimated the effect size of the prevalence of NTM with a sample size ≥40, and patients were registered in and after 2006. DATA EXTRACTION AND SYNTHESIS: Two reviewers screened the titles, abstracts and full texts independently. Relevant information was extracted and curated into tables. Risk of bias was evaluated following the Cochrane Collaboration's tool. Meta-analysis was performed with software R Statistics V.3.6.3 using random effect model with 95% CI. I
resultsOf all the 2014 studies yielded, 24 met the inclusion criteria. Of these, 14 were identified to be randomised controlled studies and included for an accurate estimation. The global prevalence of NTM in adults with non-CF bronchiectasis from 2006 to 2021 was estimated to be approximately 10%, with great variations primarily due to geographical location.
conclusionsThe prevalence of NTM in adults with non-CF bronchiectasis has been on the rise and the most common subspecies changed greatly in recent years. More cohort studies should be done in many countries and regions for future estimates. PROSPERO REGISTRATION NUMBER: CRD42020168473.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.